1
Home
Companies

Verona Pharma

#2038

Rank

$8.9B

Marketcap

GB United Kingdom

Country

Verona Pharma
Leadership team

Dr. David S. Zaccardelli (Pres, CEO & Exec. Director)

Mr. Mark W. Hahn (Chief Financial Officer)

Dr. Kathleen A. Rickard (Chief Medical Officer)

Products/ Services
Biotechnology, Pharmaceutical, Therapeutics
Headquarters
London, England, United Kingdom
Established
2005
Company Registration
SEC CIK number: 0001657312
Traded as
VRNA
Social Media
URL
https://www.veronapharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
History

Verona Pharma was incorporated in 2013 and is based in London, United Kingdom with operations in the US and EU. It is listed on the AIM market of the London Stock Exchange under the ticker code VRP.

Mission
To develop and commercialise best-in-class treatments for chronic and acute respiratory diseases that are currently inadequately served by existing therapies.
Vision
To be recognised as a trusted and innovative global leader in respiratory disease treatments.
Key Team

Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA (Gen. Counsel)

Ms. Victoria Stewart (Director of Communications)

Dr. Peter Spargo (Sr. VP of Chemistry Manufacturing & Controls)

Mr. Matthew Casbon (VP of Sales, Marketing & Training)

Dr. Tara Rheault M.P.H., Ph.D. (Sr. VP of R&D)

Ms. Ostra Jewell (Sr. VP of HR)

Ms. Nina Church (Exec. Director of Global Clinical Devel.)

Recognition and Awards
In 2020, Verona Pharma won the Scrip Award for Best Corporate Performance for the second year in a row.
References

https://in.investing.com/equities/verona-pharma-adr

https://finance.yahoo.com/quote/VRNA/profile?p=VRNA

https://www.crunchbase.com/organization/verona-pharma

https://sec.report/CIK/0001657312

https://companiesmarketcap.com/

https://www.veronapharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Verona Pharma
Leadership team

Dr. David S. Zaccardelli (Pres, CEO & Exec. Director)

Mr. Mark W. Hahn (Chief Financial Officer)

Dr. Kathleen A. Rickard (Chief Medical Officer)

Products/ Services
Biotechnology, Pharmaceutical, Therapeutics
Headquarters
London, England, United Kingdom
Established
2005
Company Registration
SEC CIK number: 0001657312
Traded as
VRNA
Social Media
URL
https://www.veronapharma.com